Welcome to our dedicated page for Novonix SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NOVONIX Limited (NVNXF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. NOVONIX files Form 6-K current reports under the Securities Exchange Act of 1934, identified by Commission File Number 001-41208. These filings typically incorporate Australian Securities Exchange (ASX) documents and other materials that describe changes in NOVONIX’s securities, governance, and corporate actions.
Recent NOVONIX 6-K filings reference ASX forms such as Appendix 2A (Application for quotation of securities), Appendix 3H (Notification of cessation of securities), and Appendix 3X (Initial Director’s Interest Notice). Through these exhibits, investors can track events including new share quotations, cessation of securities, and initial disclosures of director interests. Other 6-Ks attach ASX announcements related to board appointments and other corporate developments.
For NVNXF investors, these filings complement company news releases that discuss NOVONIX’s battery materials and technology activities, including synthetic graphite projects in Chattanooga, Tennessee, technology licensing arrangements, and financing transactions. While detailed financial statements and risk discussions are typically provided in annual and periodic reports, the 6-Ks offer interim updates on material information that NOVONIX chooses to furnish to the SEC.
On this page, Stock Titan surfaces NOVONIX’s SEC submissions as they appear on EDGAR and pairs them with AI-powered summaries to explain the practical meaning of each filing. This can help readers quickly understand whether a filing relates to new securities being quoted, changes in existing securities, director interest notices, or other corporate announcements. Users interested in insider-related disclosures can review exhibits such as Appendix 3X, while those focused on capital structure can examine Appendices 2A and 3H and their associated descriptions.
NOVONIX Ltd director Burrow Sharan has filed an initial ownership report showing a significant personal stake in the company. The Form 3 indicates direct beneficial ownership of 215,739 ordinary shares. This filing establishes Sharan’s starting equity position as a director and does not reflect any specific recent share purchase or sale.
NOVONIX Ltd director Liveris Nicholas has reported his direct ownership of the company’s ordinary shares. As of 2026-03-16, he is shown as holding 459,090 ordinary shares directly. The filing does not show any new purchase or sale activity, only the reported ownership position.
NOVONIX Ltd director Tony Bellas filed an initial statement of beneficial ownership of ordinary shares. The filing reports 95,744 ordinary shares held directly. It also reports additional ordinary share holdings indirectly through corporations controlled by him, including 230,246 shares and 2,398,145 shares, reflecting his total reported equity stake as of the filing date.
Novonix Limited filed a Form 6-K reporting a change in director shareholdings via an attached ASX Appendix 3Y. The notice covers director Nicholas Liveris, whose interest is recorded as a direct holding following an on-market trade. After this change, he holds 459,090 ordinary shares in Novonix.
Novonix Limited has reported the issue of 5,517,712 unquoted NVXAD performance rights on 13 March 2026 under its employee incentive scheme. These rights are in an existing, unquoted ASX class and rank equally with other securities in that class.
Key management personnel received a significant portion, including Robert Long with 2,069,142 performance rights, and both Kimberly Heimert and Dwayne Johnson with 1,724,285 each. Following this issue, Novonix has 861,365,155 NVX ordinary fully paid shares quoted on ASX and 28,735,426 NVXAD performance rights on issue. The issue was made under Listing Rule 7.2 exception 13, so no separate security holder approval was required.
NOVONIX Limited reports that the U.S. International Trade Commission has determined Chinese imports of anode active material do not “materially retard” the U.S. graphite industry, blocking new antidumping and countervailing duties that had been proposed by the U.S. Department of Commerce.
The company notes that a previously imposed 25% tariff under Section 301 remains, and President Trump has added a global 10% import duty under Section 122 for up to 150 days, taking the combined tariff on these imports to 35% during that period.
NOVONIX states it remains on track with its North American growth strategy, highlighting binding offtake agreements with Panasonic Energy and PowerCo and describing its synthetic graphite production capability as among the most advanced in North America, aimed at supporting domestic battery manufacturers and eligibility for 45X production tax credits.
Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y notice showing a change in director Nicholas Liveris’s shareholding. The filing states that the change arose from an on‑market trade and that he now holds 559,090 ordinary shares as a direct interest.
NOVONIX LIMITED has issued 451,991 new ordinary fully paid shares (ASX code NVX) on 11/03/2026 following the conversion of performance rights under an employee incentive scheme. The shares were issued for non-cash consideration, with an estimated value of AUD 0.30 per share.
After this issue, the company has 861,365,155 NVX ordinary shares quoted on ASX. It also has unquoted performance rights, options with various terms, and convertible notes remaining on issue, which may lead to further share issuances if converted or exercised.
NOVONIX Limited filed a Form 6-K describing an exclusive access agreement to evaluate purchasing 17.5 acres of land directly adjacent to its Riverside anode materials facility in Chattanooga, Tennessee. The potential purchase price for the adjacent land is US$26.5 million, contingent on completing due diligence and deciding to proceed.
NOVONIX will pay US$100,000 for at least 150 days of exclusive due diligence and will assess whether the land can be re-zoned to heavy industrial use. The company states there is no certainty the transaction will proceed and will provide further updates under its continuous disclosure obligations.
NOVONIX Limited filed a Form 6-K reporting an Appendix 3Y notice to the ASX about a change in a director’s shareholding. The notice shows director Nicholas Liveris now has a relevant interest in 589,142 ordinary shares held directly following an on-market trade.
The filing confirms there was no trading during a closed period that required prior written clearance.